8-K: Avalo Therapeutics Reports Positive Phase 2 Trial Results for Abdakibart

Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial for abdakibart in moderate to severe hidradenitis suppurativa, meeting primary endpoints and demonstrating a favorable safety profile.

Summary

• Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial evaluating abdakibart for moderate to severe hidradenitis suppurativa (HS).
• The trial successfully met its primary endpoint, the proportion of patients achieving HiSCR75 at Week 16, with response rates of 42.2% for the 150 mg dose and 42.9% for the 300 mg dose.
• These response rates represent the highest absolute improvement observed in trials of similar or larger size.
• Key secondary endpoints, including HiSCR50, change in IHS4, and change in draining tunnel count, also showed statistically significant benefits.
• Abdakibart was well-tolerated with a favorable safety profile, with no adverse events related to neutropenia, serious infections, or opportunistic infections.
• The company plans to advance abdakibart into a registrational Phase 3 program based on these promising results.
• The LOTUS trial enrolled 253 adults and was a randomized, double-blind, placebo-controlled study over a 16-week treatment period.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, with strong efficacy data and a favorable safety profile from a Phase 2 trial, paving the way for a pivotal Phase 3 program.

Positives

• Successfully met the primary endpoint (HiSCR75) for both abdakibart doses studied, achieving 42.2% (150 mg) and 42.9% (300 mg) response rates at Week 16.
• Achieved the highest absolute improvement in HiSCR75 and HiSCR50 rates observed in clinical trials of this size or larger.
• Demonstrated statistically significant benefits across key secondary endpoints, including HiSCR50, change in IHS4, and change in draining tunnel count.
• Abdakibart showed a favorable safety profile, with treatment-emergent adverse events (TEAEs) similar to placebo and no unexpected safety findings.
• No adverse events related to neutropenia, serious infections, or opportunistic infections were reported.
• Response rates were consistent across different doses and similar in patients with and without prior biologic exposure.
• The drug was well-tolerated, with most adverse events being mild to moderate.
• The company plans to advance abdakibart into a registrational Phase 3 program, indicating strong confidence in the drug's potential.

Negatives

• While the trial met its primary endpoint, the placebo response rate was 25.6% for HiSCR75, indicating a significant unmet need and the challenge of differentiating treatment effects.
• The press release and presentation exclude certain paragraphs and details, potentially omitting specific nuances or additional data points.
• Cross-trial comparisons are noted as having limitations due to differences in trial design, patient populations, and protocols, making direct comparisons to other therapies inherently difficult.

Risks

• The risk that the results of prior preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical studies and clinical trials, including those for abdakibart.
• The risk that cross-trial comparisons may not be reliable as no head-to-head trials of abdakibart have been conducted.
• The timing and outcome of any interactions with regulatory authorities.
• Obtaining, maintaining, and protecting intellectual property.
• The availability of funding sufficient for operating expenses and capital expenditure requirements.
• Reliance on key personnel.
• General economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East.

Future Outlook

Avalo plans to advance abdakibart into a registrational Phase 3 program based on the positive Phase 2 LOTUS trial results. The company expects to present full results at an upcoming medical congress.

Management Comments

• "We are proud to report that abdakibart has delivered a strong, consistent, and deep response across both the HiSCR75 and HiSCR50 endpoints in our Phase 2 trial. This achievement powerfully validates the clinical promise of IL-1 inhibition for hidradenitis suppurativa."
• "This de-risking data set gives us tremendous confidence to advance abdakibart into a pivotal phase 3 registrational program. With a differentiated and patient friendly potential monthly dosing regimen, we aim to offer a truly innovative mechanism of action to the HS community."
• "Our heartfelt thank you goes to the patients, caregivers, investigators, and site teams whose dedication made this successful Phase 2 trial possible."

Industry Context

StockSavvy.ai notes that the positive results for abdakibart in hidradenitis suppurativa are significant, as HS is a chronic and debilitating inflammatory skin disease with a projected global therapeutics market of over $10 billion by 2035. The company's focus on IL-1 inhibition aligns with a growing understanding of the role of specific cytokines in immune-mediated inflammatory diseases.

Comparison to Industry Standards

• The Phase 2 LOTUS trial reported HiSCR75 response rates of 42.2% (150 mg) and 42.9% (300 mg), which are presented as the highest absolute response rates observed in trials of similar or larger size compared to other investigational and approved therapies.
• Cross-trial comparisons show abdakibart's HiSCR75 response rates (42.2% and 42.9%) are competitive with or higher than those reported for approved therapies like adalimumab (35%), secukinumab (36%), and bimekizumab (35%), and select pipeline therapies like sonelokimab (46%) and povorcitinib (39%).
• Similarly, HiSCR50 response rates for abdakibart (59.0% and 64.3%) appear strong when compared to reported rates for other treatments, though direct head-to-head comparisons are not available.

Stakeholder Impact

• Shareholders: Positive news is likely to be viewed favorably, potentially impacting stock price positively due to progress in drug development.
• Patients with Moderate to Severe Hidradenitis Suppurativa: Potential for a new, effective, and well-tolerated treatment option with a patient-friendly dosing regimen.
• Healthcare Providers: May see abdakibart as a promising new therapeutic option to offer patients struggling with HS.
• Competitors: The positive results may intensify competition in the HS treatment market.

Next Steps

• Advance abdakibart into a registrational Phase 3 program.
• Present full results from the LOTUS trial at an upcoming medical congress.

Key Dates

Recommendation

The positive topline results from the Phase 2 LOTUS trial, demonstrating statistically significant efficacy and a favorable safety profile for abdakibart in moderate to severe hidradenitis suppurativa, are highly encouraging. The company's clear plan to advance into a Phase 3 registrational program, coupled with the drug's competitive positioning against existing therapies, suggests strong potential for future success and market penetration. This de-risked data set provides a solid foundation for continued investment and development.

Keywords

Hidradenitis Suppurativa, Abdakibart, Avalo Therapeutics, Phase 2 Trial, Biotechnology, Inflammatory Disease, Clinical Trial Results, IL-1 Inhibition